Highest-materiality recent filing
Quince Therapeutics schedules special meeting for Series C conversion and share issuance
Quince Therapeutics will hold a special meeting to approve issuance of shares upon conversion of 211,301.868 Series C Preferred shares into 10,987,728 common shares.
Quince Therapeutics Q2 2026: Net loss $75.5M, cash $116M, Orphai acquisition closed
Completed stock-for-stock Orphai acquisition adding LAM-001 inhaled rapamycin; concurrent $115M private placement, net $103.6M.
CEO Dirk Thye and COO Brendan Hannah tender conditional resignations effective two business days after Sept 25, 2026 special meeting, contingent on stockholder approval of three proposals.
Quince Therapeutics files Orphai acquisition financials; pipeline details disclosed
Audited Orphai financials for FY2024-2025 and unaudited Q1 2026 now filed; pro forma combined financials included.
Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%
Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.
Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts
Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.
Quince settles $16.4M EIB debt for $5.5M, eliminates debt overhang
Paid $5.5M to settle ~$16.4M in EIB debt obligations, a discount of roughly $10.9M.
Quince Therapeutics receives two Nasdaq deficiency notices with 180-day cure periods
Bid Price Notice: common stock closing bid below $1.00 for 30 consecutive business days; cure by Sept 14, 2026.
Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger
As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.
Five directors resign from Quince Therapeutics board effective immediately
Directors Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray resigned on Jan 30, 2026.
Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted
Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.
Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data
Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.
Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M
Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.
Quince completes Phase 3 NEAT enrollment with 105 patients; topline results Q1 2026
Enrolled 105 participants total; 83 in primary analysis (ages 6-9), 22 aged 10+.
Quince raises $11.5M in private placement of stock and warrants; management participates
Sold 6,671,928 shares, 2M pre-funded warrants, and 8,671,928 common warrants for $11.5M gross proceeds.
63 participants enrolled to date (56 in primary analysis population ages 6–9); original target was 86.
Quince Therapeutics FY2024 net loss $56.8M; Phase 3 NEAT trial exceeds 50% enrollment
Net loss of $56.8M ($1.31/share) for FY2024; cash $40.8M provides runway into 2026.
Quince Therapeutics regains Nasdaq minimum bid price compliance; delisting risk removed
On Nov 12, 2024, Nasdaq confirmed Quince regained compliance with $1.00 minimum bid price rule.
Quince Therapeutics Q3 net loss $5.5M; Phase 3 NEAT enrollment at 32 patients
Phase 3 NEAT trial enrolled 32 patients; on track to complete enrollment in Q2 2025 with topline results in Q4 2025.
Quince Therapeutics Q2 net loss $27.7M; Phase 3 NEAT on track for Q4 2025 topline
Cash $59.4M at June 30; expects runway into 2026 through Phase 3 NEAT topline results.
Quince Therapeutics receives Nasdaq delisting notice for bid price non-compliance
Received Nasdaq notice for non-compliance with $1.00 minimum bid price requirement.
Quince provides EryDel historical financials; FY2022 loss of €12.5M
EryDel net loss of €12.5M in 2022 vs. €17.3M in 2021; accumulated deficit €76.5M.
Quince Therapeutics terminates exclusive worldwide license for NOV004 bone fracture repair program
Termination effective October 31, 2023, following prior decision to discontinue internal development of NOV004.
Received Nasdaq notice on Dec 4, 2023 for failing minimum bid price of $1.00 for 30 consecutive trading days.
Quince Therapeutics closes acquisition of EryDel for up to $485M in milestones
Issued 6,525,315 shares (15.2% ownership) to EryDel shareholders; up to 725,036 more shares at first anniversary.
Quince Therapeutics to acquire EryDel for up to 7.25M shares + $485M milestones
EryDel shareholders get up to 7,250,352 shares (16.7% of combined company) and up to $485M in milestone cash payments, no royalties.
Quince Therapeutics adopts one-year poison pill after unsolicited bid, share accumulation
Rights plan effective immediately, expires April 5, 2024; dividend of one right per share on April 17, 2023.
Quince Therapeutics cuts workforce 47%; reports $94M cash; pivots to in-licensing
Preliminary unaudited cash, cash equivalents, and marketable securities of ~$94M as of Dec 31, 2022.
Received 7.5% of Lighthouse common stock; eligible for up to $150M in milestone payments.
On August 23, 2026, Quince Therapeutics, Inc. (the “Company”) and Charles Ryan, the Company’s President, determined that Mr. Ryan’s last day of employment will be September 8, 2026.
each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company
John Militello, CPA , age 52, was conditionally appointed as the Company’s Chief Financial Officer
Brigette Roberts, M.D. , age 50, was conditionally appointed as the Company’s Chief Executive Officer
each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company
Conditional Appointments of Brigette Roberts, John Militello and Keith Fandrick
Brigette Roberts, M.D., was appointed to the Board as a Class III director.
Dr. Roberts was also appointed as the Chief of Corporate Affairs of the Company.
the board of directors (the “ Board ”) of Quince Therapeutics, Inc. (the “ Company ”) appointed Rajiv Patni to serve as a director of the Company, effective as of February 15, 2024.
On October 24, 2023, the Board of Directors of Quince Therapeutics, Inc. (the “Company”) appointed Brendan Hannah to the position of Chief Operating Officer of the Company.
appointed Luca Benatti to serve as a director of the Company, effective as of the first business day following the closing of the EryDel Acquisition.
On August 30, 2023, the Board of Directors of the Company approved the appointment of Charles S. Ryan, Ph.D., as the President of the Company, effective as of September 1, 2023.
Max materiality 1.00 · Median 0.65 · Most common event other_material